149 related articles for article (PubMed ID: 28881753)
41. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
42. α-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells.
Michikoshi H; Nakamura T; Sakai K; Suzuki Y; Adachi E; Matsugo S; Matsumoto K
Cancer Lett; 2013 Jul; 335(2):472-8. PubMed ID: 23507559
[TBL] [Abstract][Full Text] [Related]
43. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
Hwang KE; Kwon SJ; Kim YS; Park DS; Kim BR; Yoon KH; Jeong ET; Kim HR
Exp Cell Res; 2014 May; 323(2):288-96. PubMed ID: 24631288
[TBL] [Abstract][Full Text] [Related]
44. Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal Cancer.
Kripp M; Merx K; Wirtz RM; Gaiser T; Eidt S; Schwaab J; Post S; Wenz F; Hochhaus A; Hofheinz RD; Erben P
Gastroenterol Res Pract; 2016; 2016():3481578. PubMed ID: 27610130
[TBL] [Abstract][Full Text] [Related]
45. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
46. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P
Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924
[TBL] [Abstract][Full Text] [Related]
47. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
[TBL] [Abstract][Full Text] [Related]
48. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
Liu B; Ordonez-Ercan D; Fan Z; Edgerton SM; Yang X; Thor AD
Int J Cancer; 2007 May; 120(9):1874-82. PubMed ID: 17266042
[TBL] [Abstract][Full Text] [Related]
49. The upgraded role of HER3 and HER4 receptors in breast cancer.
Koutras AK; Fountzilas G; Kalogeras KT; Starakis I; Iconomou G; Kalofonos HP
Crit Rev Oncol Hematol; 2010 May; 74(2):73-8. PubMed ID: 19481955
[TBL] [Abstract][Full Text] [Related]
50. Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials.
Maennling AE; Tur MK; Niebert M; Klockenbring T; Zeppernick F; Gattenlöhner S; Meinhold-Heerlein I; Hussain AF
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31756933
[TBL] [Abstract][Full Text] [Related]
51. The broad-spectrum metalloproteinase inhibitor BB-94 inhibits growth, HER3 and Erk activation in fulvestrant-resistant breast cancer cell lines.
Kirkegaard T; Yde CW; Kveiborg M; Lykkesfeldt AE
Int J Oncol; 2014 Jul; 45(1):393-400. PubMed ID: 24819550
[TBL] [Abstract][Full Text] [Related]
52. Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells.
Bachawal SV; Wali VB; Sylvester PW
BMC Cancer; 2010 Mar; 10():84. PubMed ID: 20211018
[TBL] [Abstract][Full Text] [Related]
53. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
Zhou G; Zhang F; Guo Y; Huang J; Xie Y; Yue S; Chen M; Jiang H; Li M
Biomed Pharmacother; 2017 Jan; 85():113-119. PubMed ID: 27930974
[TBL] [Abstract][Full Text] [Related]
54. Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells.
Ariyama H; Qin B; Baba E; Tanaka R; Mitsugi K; Harada M; Nakano S
J Cell Biochem; 2006 Mar; 97(4):724-34. PubMed ID: 16229013
[TBL] [Abstract][Full Text] [Related]
55. Mutations of EGFR in lung cancers and their implications for targeted therapy.
Shigematsu H; Gazdar AF
Discov Med; 2004 Dec; 4(24):444-7. PubMed ID: 20704946
[TBL] [Abstract][Full Text] [Related]
56. Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.
Romaniello D; Marrocco I; Belugali Nataraj N; Ferrer I; Drago-Garcia D; Vaknin I; Oren R; Lindzen M; Ghosh S; Kreitman M; Kittel JC; Gaborit N; Bergado Baez G; Sanchez B; Eilam R; Pikarsky E; Paz-Ares L; Yarden Y
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32847130
[TBL] [Abstract][Full Text] [Related]
57. Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2
Yu X; Ghamande S; Liu H; Xue L; Zhao S; Tan W; Zhao L; Tang SC; Wu D; Korkaya H; Maihle NJ; Liu HY
Mol Ther Nucleic Acids; 2018 Mar; 10():317-330. PubMed ID: 29499944
[TBL] [Abstract][Full Text] [Related]
58. HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285.
Takagi S; Banno H; Hayashi A; Tamura T; Ishikawa T; Ohta Y
Oncoscience; 2014; 1(3):196-204. PubMed ID: 25594012
[TBL] [Abstract][Full Text] [Related]
59. Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.
Jathal MK; Chen L; Mudryj M; Ghosh PM
Immunol Endocr Metab Agents Med Chem; 2011 Jun; 11(2):131-149. PubMed ID: 21603064
[TBL] [Abstract][Full Text] [Related]
60. Activating HER3 mutations in breast cancer.
Mishra R; Alanazi S; Yuan L; Solomon T; Thaker TM; Jura N; Garrett JT
Oncotarget; 2018 Jun; 9(45):27773-27788. PubMed ID: 29963236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
